ABSTRACT
Aprotinin aerosol has been previously shown to have protective effects in experimental influenza- and parainfluenza-induced bronchopneumonias in animals. This paper presents the results of controlled clinical studies to evaluate the therapeutical efficiency of aprotinin aerosol in natural influenza and parainfluenza infections in human beings. A total of 52 patients were followed up. They received either soda (placebo) or aprotinin inhalations thrice a day for 4-5 days. The following mean duration (in days) of symptoms was found in the control (placebo-treated) and aprotinin-treated patients. These were: 2.5 versus 1.8 for fever, 2.0 versus 1.5 for headache, 2.9 versus 1.8 for weakness, 3.9 and 2.8 for common cold, 3.1 versus 1.6 for sore throat, 4.9 versus 2.8 for pharyngeal hyperemia, 4.9 versus 4.0 for cough, and 3.5 versus 1.3 for hoarse voice (p < 0.05). Inhaled aprotinin was well tolerated by the patients and caused no topical irritating effects and allergic reactions. The findings demonstrate the noticeable clinical efficacy of aprotinin aerosol in human influenza and parainfluenza.
Subject(s)
Antiviral Agents/administration & dosage , Aprotinin/administration & dosage , Influenza, Human/drug therapy , Paramyxoviridae Infections/drug therapy , Serine Proteinase Inhibitors/administration & dosage , Trypsin Inhibitors/administration & dosage , Adolescent , Adult , Aerosols , Female , Follow-Up Studies , Humans , Male , Middle Aged , Time FactorsABSTRACT
Inhalations of natural protease inhibitor aprotinin in the form of finely divided aerosol against acute respiratory infections caused by influenza virus, parainfluenza viruses, adenoviruses, and mixed infections produced subjective effect as early as the treatment day 1. Objectively, aprotinin therapy was associated with a 1.5-2-fold reduction in the duration of systemic and respiratory symptoms compared to placebo. As a rule, the inhalations were well tolerated and caused neither local irritation nor allergy. No hepatic, hematopoietic toxicity has been documented. Aprotinin inhalations are thought promising against influenza and acute respiratory infections.
Subject(s)
Aprotinin/administration & dosage , Respiratory Tract Infections/drug therapy , Virus Diseases/drug therapy , Acute Disease , Administration, Inhalation , Adolescent , Adult , Aerosols , Aprotinin/adverse effects , Drug Evaluation , Female , Humans , Male , Middle Aged , Respiratory Tract Infections/blood , Respiratory Tract Infections/etiology , Virus Diseases/blood , Virus Diseases/etiologyABSTRACT
Leukinferon activity was studied in a controlled trial including 30 patients with acute viral hepatitis. The disease ran a moderate severity course in the majority of the patients. Leukinferon, a combined preparation of natural interferon and cytokines produced by virus-induced leukocytes, has marked immunomodulating properties at moderate antiviral activity. Leukinferon was administered intramuscularly for 10 days according to the following scheme: day 1-1 sample 3 times, day 2-1 ampule 2 times, day 3-10-1 ampule a day (overall 1 x 10(5) U of interferon). Due to leukinferon the symptoms of intoxication declined, hepatic biochemistry normalized more rapidly as well as the period of viremia and antigenemia. Positive clinical trends correlated with interferon system improvement and activation of natural killers. 6 months later complete recovery was registered in all leukinferon-treated subjects.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Cytokines/therapeutic use , Hepatitis B/therapy , Interferon Type I/therapeutic use , Acute Disease , Adult , Double-Blind Method , Drug Administration Schedule , Drug Combinations , Female , Follow-Up Studies , Humans , Injections, Intramuscular , Male , Severity of Illness Index , Treatment OutcomeSubject(s)
Antiviral Agents/therapeutic use , Cytomegalovirus Infections/drug therapy , Pregnancy Complications, Infectious/drug therapy , Antibodies, Viral/analysis , Antiviral Agents/administration & dosage , Cytomegalovirus/drug effects , Cytomegalovirus/immunology , Cytomegalovirus Infections/immunology , Female , Humans , Pregnancy , Pregnancy Complications, Infectious/immunology , Rosette Formation , T-Lymphocytes/immunologySubject(s)
Flavonoids/therapeutic use , Hepatitis B/drug therapy , Lipid Peroxidation/drug effects , Liver/metabolism , Quercetin/therapeutic use , Adolescent , Adult , Aged , Antioxidants , Female , Hepatitis B/metabolism , Humans , Lipid Peroxidation/physiology , Liver/drug effects , Male , Middle AgedSubject(s)
Ambulatory Care , Hepatitis A/therapy , Patient Discharge , Adolescent , Adult , Female , Follow-Up Studies , Humans , Male , Time FactorsABSTRACT
The use of immunoautoradiography for HBsAg detection increased its primary detection rate in the blood of patients with acute serum hepatitis to 70% (by 12--15% more than in the gel precipitation test). Antigenemia in patients with acute serum hepatitis has been shown to last much longer than could be determined by gel precipitation. As a result of this, over 60% of the patients with HBs-antigenemia in the acute period are discharged from the hospital still containing the antigen. A correlation between the duration of antigenemia in the GP test and the speed of antigen disappearance from the blood according to the IAR test was established. The IAR method was found to be highly sensitive and specific; its application helps solving some theoretical and practical problems.